SI2126093T1 - Izboljšanje priprave proteinov - Google Patents

Izboljšanje priprave proteinov

Info

Publication number
SI2126093T1
SI2126093T1 SI200830858T SI200830858T SI2126093T1 SI 2126093 T1 SI2126093 T1 SI 2126093T1 SI 200830858 T SI200830858 T SI 200830858T SI 200830858 T SI200830858 T SI 200830858T SI 2126093 T1 SI2126093 T1 SI 2126093T1
Authority
SI
Slovenia
Prior art keywords
improvement
protein production
protein
production
Prior art date
Application number
SI200830858T
Other languages
English (en)
Inventor
Hitto Kaufmann
Lore Florin
Eric Becker
Monilola Olayioye
Angelika Hausser
Tim Fugmann
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07103406A external-priority patent/EP1964922A1/en
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of SI2126093T1 publication Critical patent/SI2126093T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
SI200830858T 2007-03-02 2008-02-29 Izboljšanje priprave proteinov SI2126093T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07103406A EP1964922A1 (en) 2007-03-02 2007-03-02 Improvement of protein production
EP07104226 2007-03-15
EP07116358 2007-09-13
PCT/EP2008/052493 WO2008107388A1 (en) 2007-03-02 2008-02-29 Improvement of protein production
EP08717274A EP2126093B1 (en) 2007-03-02 2008-02-29 Improvement of protein production

Publications (1)

Publication Number Publication Date
SI2126093T1 true SI2126093T1 (sl) 2013-01-31

Family

ID=39639553

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830858T SI2126093T1 (sl) 2007-03-02 2008-02-29 Izboljšanje priprave proteinov

Country Status (24)

Country Link
US (4) US20130177919A1 (sl)
EP (3) EP2522729A1 (sl)
JP (1) JP5467415B2 (sl)
KR (1) KR20100015363A (sl)
AR (2) AR065573A1 (sl)
AU (1) AU2008223874B2 (sl)
BR (1) BRPI0808542A2 (sl)
CA (1) CA2677925A1 (sl)
CY (1) CY1113710T1 (sl)
DK (1) DK2126093T3 (sl)
EA (1) EA018190B1 (sl)
ES (1) ES2397274T3 (sl)
HK (1) HK1136314A1 (sl)
HR (1) HRP20121077T1 (sl)
IL (1) IL200030A0 (sl)
MX (1) MX2009009156A (sl)
MY (1) MY148472A (sl)
NZ (1) NZ580043A (sl)
PL (1) PL2126093T3 (sl)
PT (1) PT2126093E (sl)
SG (1) SG182160A1 (sl)
SI (1) SI2126093T1 (sl)
TW (1) TWI419902B (sl)
WO (1) WO2008107388A1 (sl)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130177919A1 (en) 2007-03-02 2013-07-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Protein production
AR073564A1 (es) * 2008-09-10 2010-11-17 Boehringer Ingelheim Pharma Uso de celulas productoras de hsa (albumina de suero humano)
WO2010128032A1 (en) * 2009-05-05 2010-11-11 Boehringer Ingelheim International Gmbh Cho / cert cell lines
EP2430165A1 (en) * 2009-05-15 2012-03-21 Boehringer Ingelheim International GmbH Combinatorial engineering
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US8506797B2 (en) * 2011-04-10 2013-08-13 Therapeutic Proteins International, LLC Downstream bioprocessing device
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013052523A1 (en) 2011-10-03 2013-04-11 modeRNA Therapeutics Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SMT201800307T1 (it) 2011-10-28 2018-09-13 Prothena Biosciences Ltd Anticorpi umanizzati che riconoscono alfa-sinucleina
US8852435B2 (en) * 2011-11-29 2014-10-07 Therapeutics Proteins International, LLC Purification and separation treatment assembly (PASTA) for biological products
SG11201402666WA (en) 2011-12-16 2014-10-30 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions
NZ629296A (en) 2012-01-27 2016-06-24 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
KR101438533B1 (ko) * 2012-03-30 2014-09-17 한양대학교 산학협력단 적혈구계 세포의 인 비트로 확장방법
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2833920A2 (en) 2012-04-02 2015-02-11 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US8886625B1 (en) 2012-10-31 2014-11-11 Google Inc. Methods and computer-readable media for providing recommended entities based on a user's social graph
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
US8972368B1 (en) 2012-12-07 2015-03-03 Google Inc. Systems, methods, and computer-readable media for providing search results having contacts from a user's social graph
KR102313513B1 (ko) 2013-03-13 2021-10-15 프로테나 바이오사이언시즈 리미티드 Tau 면역치료제
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
EP3071974A2 (en) 2013-11-19 2016-09-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
CA2938931A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
DK3116911T3 (da) 2014-03-12 2019-09-30 Prothena Biosciences Ltd Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
EP3129051A1 (en) 2014-04-08 2017-02-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
TW202204596A (zh) 2014-06-06 2022-02-01 美商健臻公司 灌注培養方法及其用途
TWI707949B (zh) * 2014-06-09 2020-10-21 美商健臻公司 種子罐培養法（ｓｅｅｄ ｔｒａｉｎ ｐｒｏｃｅｓｓｅｓ）及其用途
TWI781507B (zh) 2015-01-28 2022-10-21 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI711631B (zh) 2015-01-28 2020-12-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
MX2018013386A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
CN109219615B (zh) 2016-05-02 2022-12-09 普罗塞纳生物科学有限公司 识别tau的抗体
CA3022673A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
EP3478715A2 (en) 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007924A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7076711B2 (ja) 2016-07-02 2022-05-30 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
AU2018241920B2 (en) * 2017-03-29 2022-04-21 Boehringer Ingelheim Rcv Gmbh & Co Kg Recombinant host cell with altered membrane lipid composition
CA3061516A1 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
WO2019064053A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES
KR102581734B1 (ko) 2017-10-06 2023-09-22 네오토프 뉴로사이언스 리미티드 트랜스타이레틴의 검출 방법
WO2019079165A1 (en) * 2017-10-16 2019-04-25 Regeneron Pharmaceuticals, Inc. RAMAN IN SITU SPECTROSCOPY SYSTEMS AND METHODS FOR CONTROLLING PROCESSING VARIABLES IN CELL CULTURES
PL3817773T3 (pl) 2018-11-26 2024-10-28 Forty Seven, Inc. Humanizowane przeciwciała przeciwko c-kit
CN113544149B (zh) 2019-03-03 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
CN110592044B (zh) * 2019-07-26 2021-06-22 中国农业科学院蔬菜花卉研究所 蛋白激酶Fused编码基因及其在防治小菜蛾中的应用
CN111100865B (zh) * 2020-01-07 2022-03-18 江南大学 一种提高酿酒酵母丁醇耐受能力的方法
JP2023533458A (ja) 2020-06-24 2023-08-03 プロシーナ バイオサイエンシーズ リミテッド ソルチリンを認識する抗体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521297A (en) * 1993-06-04 1996-05-28 Salk Institute Biotechnology/Industrial Associates Nucleic acids encoding human metabotropic glutamate receptors
US5869250A (en) * 1996-12-02 1999-02-09 The University Of North Carolina At Chapel Hill Method for the identification of peptides that recognize specific DNA sequences
DE60025704T2 (de) * 1999-02-24 2006-09-07 Juan Saus Das goodpasture-antigen bindende protein
EP1514933A1 (en) * 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
US8021658B2 (en) * 2001-05-25 2011-09-20 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
WO2004045543A2 (en) * 2002-11-14 2004-06-03 Dharmacon, Inc. Functional and hyperfunctional sirna
WO2004070025A2 (en) * 2003-02-05 2004-08-19 Juan Saus Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
WO2004111194A2 (en) 2003-06-11 2004-12-23 Biogen Idec Ma Inc. Method to increase protein production in culture
US7244616B2 (en) * 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
JP2005035926A (ja) 2003-07-14 2005-02-10 Japan Science & Technology Agency セラミド輸送を促進する薬剤、該薬剤を製造する塩基配列、セラミド遊離を促進する活性の測定方法、及びセラミドの膜間移動を促進する活性の測定方法
AU2005248147A1 (en) * 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
KR20100084706A (ko) * 2005-06-20 2010-07-27 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
US20090018099A1 (en) * 2007-03-02 2009-01-15 Hitto Kaufmann Protein production
US20130177919A1 (en) 2007-03-02 2013-07-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Protein production
WO2010128032A1 (en) 2009-05-05 2010-11-11 Boehringer Ingelheim International Gmbh Cho / cert cell lines

Also Published As

Publication number Publication date
WO2008107388A1 (en) 2008-09-12
CA2677925A1 (en) 2008-09-12
AR065573A1 (es) 2009-06-17
EP2522729A1 (en) 2012-11-14
SG182160A1 (en) 2012-07-30
JP2010519917A (ja) 2010-06-10
AR086476A2 (es) 2013-12-18
US20130196430A1 (en) 2013-08-01
CY1113710T1 (el) 2016-06-22
US8221999B2 (en) 2012-07-17
IL200030A0 (en) 2011-08-01
NZ580043A (en) 2012-04-27
AU2008223874A1 (en) 2008-09-12
PT2126093E (pt) 2012-12-03
EA200901168A1 (ru) 2010-06-30
PL2126093T3 (pl) 2013-03-29
MX2009009156A (es) 2009-09-04
KR20100015363A (ko) 2010-02-12
HRP20121077T1 (hr) 2013-01-31
US20130177919A1 (en) 2013-07-11
BRPI0808542A2 (pt) 2014-08-26
DK2126093T3 (da) 2013-01-07
US20080300207A1 (en) 2008-12-04
HK1136314A1 (en) 2010-06-25
TW200846368A (en) 2008-12-01
JP5467415B2 (ja) 2014-04-09
MY148472A (en) 2013-04-30
AU2008223874B2 (en) 2014-06-26
EA018190B1 (ru) 2013-06-28
US20130197196A1 (en) 2013-08-01
EP2126093A1 (en) 2009-12-02
ES2397274T3 (es) 2013-03-05
TWI419902B (zh) 2013-12-21
EP2522730A1 (en) 2012-11-14
EP2126093B1 (en) 2012-10-10

Similar Documents

Publication Publication Date Title
HK1136314A1 (en) Improvement of protein production
HRP20171701T8 (hr) Metode za poboljšanu proizvodnju proteina
IL201719A0 (en) Methods of protein production using anti-senescence compounds
HK1214307A1 (zh) 糖蛋白的產生
HK1218558A1 (zh) 蛋白
EP2586428C0 (en) Production of several mini capsules
HK1136696A1 (en) Production
GB0702695D0 (en) Production of vectors
GB0711697D0 (en) Method of manufacture
EP2285824A4 (en) PRODUCTION OF PROTEIN ISOLATES
HK1143309A1 (en) Thermostabilization of proteins
GB0816976D0 (en) Protein
IL240134A0 (en) new proteins
ZA201109283B (en) Protein
GB0724953D0 (en) Methods of peptide modification
GB0909502D0 (en) Novel protein crystallization technique
GB0712635D0 (en) Production of caseinate
GB0816419D0 (en) Production of hydroelecticity
PL382168A1 (pl) Sposób wytwarzania S-(-)- 8-metoksy -2 tetralolu
GB0903809D0 (en) Production of protein
GB0916305D0 (en) Production of protein
GB0607100D0 (en) Protein production
IL206541A0 (en) Novel protein
SI2041270T1 (sl) Proizvodnja glikoproteinov
GB0909384D0 (en) Protein